The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
OTEZLA | Skilarence® | Methotrexate | Acitretin | Cyclosporine |
|
---|---|---|---|---|---|
Treatment considerations | |||||
Indicated for PsO and PsA | |||||
Titration period | 5 days | Up to 9 weeks | Up to 8 weeks | ||
No label-required laboratory prescreening or ongoing monitoring* | |||||
Warnings and precautions |
|
|
|
|
|
aPregnancy category X (contraception starting 1 month before treatment and 2-year wait period after cessation to become pregnant).
*Regular monitoring is recommended for patients who are underweight at the start of treatment.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.